(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
IMMIX Biopharma's earnings in 2026 is -$23,562,837.On average, 4 Wall Street analysts forecast IMMX's earnings for 2026 to be -$16,097,232, with the lowest IMMX earnings forecast at -$21,389,105, and the highest IMMX earnings forecast at -$10,224,462. On average, 3 Wall Street analysts forecast IMMX's earnings for 2029 to be $35,276,913, with the lowest IMMX earnings forecast at $33,893,505, and the highest IMMX earnings forecast at $36,314,470.
In 2030, IMMX is forecast to generate $46,579,225 in earnings, with the lowest earnings forecast at $44,752,589 and the highest earnings forecast at $47,949,203.